Friday | Nov 22 2024 |
Patients treated with Nimotuzumab alongside concurrent radiotherapy and cisplatin showed a 10-year overall survival rate of 33.5 per cent, compared to 22.5 per cent for those who received only radiotherapy and cisplatin
Subscribe to our newsletter to get updates on our latest news
_20240730163304_original_image_14.webp)
